Valuation : Alamar Biosciences, Inc.

Market Cap 2.04B 1.76B 1.66B 1.51B 2.82B 192B 2.84B 19.6B 7.61B 98.4B 7.65B 7.48B 323B P/E 2026 *
-24.1x
P/E 2027 * -42.4x
Enterprise Value 1.85B 1.6B 1.5B 1.37B 2.56B 175B 2.58B 17.8B 6.91B 89.34B 6.95B 6.79B 293B EV / Sales 2026 *
15.6x
EV / Sales 2027 * 11.4x
Free-Float
78.58%
Yield 2026 *
-
Yield 2027 * -
1 day+3.93%
1 week-10.61%
Current month-0.25%
1 month+12.54%
3 months+46.47%
1 week 29.15
Extreme 29.15
34.98
1 month 24.85
Extreme 24.85
38.54
Current year 18.84
Extreme 18.845
38.54
1 year 18.84
Extreme 18.845
38.54
3 years 18.84
Extreme 18.845
38.54
5 years 18.84
Extreme 18.845
38.54
10 years 18.84
Extreme 18.845
38.54
Manager TitleAgeSince
Chief Operating Officer 63 01/08/2018
Chief Tech/Sci/R&D Officer - 01/01/2021
Chief Executive Officer 62 01/07/2018
Director TitleAgeSince
Chairman 62 01/07/2018
Director/Board Member 64 01/05/2020
Director/Board Member 66 28/08/2026
Date Insider Type Main position Quantity % Market Cap. Importance
20/4/26 Others

Director

206,781 --
20/4/26 Others

Director

206,781 7.4927%
20/4/26 Others

Director

140,612 5.0951%
Change 5-day change 1-year change 3-year change Capi.($)
+4.02%-10.61% - - 2.04B
+1.27%-3.95%+24.85%+12.30% 222B
+1.48%-2.60%+2.92%-19.59% 145B
+1.69%+0.22%-20.86%+20.65% 130B
+0.61%+0.76%-54.50%-8.94% 69.68B
+0.06%-0.09%+10.92%+19.39% 52.3B
+0.41%+0.51%-14.70%-13.41% 50.71B
+0.96%-2.91%+20.25%+26.82% 42.28B
+1.47%-0.71%+38.70%+48.81% 39.87B
+0.13%-1.69%-14.50%+50.56% 33.37B
Average +1.05%-2.22%-0.77%+15.18% 78.82B
Weighted average by Cap. +0.92%-1.61%+1.48%+8.97%

Financials

2026 *2027 *
Net sales 119M 102M 96.37M 87.8M 164M 11.2B 165M 1.14B 443M 5.73B 445M 436M 18.81B 166M 143M 135M 123M 229M 15.65B 231M 1.59B 619M 8B 622M 609M 26.29B
Net income -64.94M -56.02M -52.78M -48.08M -89.88M -6.13B -90.55M -625M -242M -3.14B -244M -239M -10.3B -49.86M -43.02M -40.52M -36.92M -69.01M -4.71B -69.53M -480M -186M -2.41B -187M -183M -7.91B
Net Debt -188M -162M -153M -139M -260M -17.73B -262M -1.81B -701M -9.06B -705M -689M -29.77B -156M -135M -127M -115M -216M -14.73B -217M -1.5B -582M -7.53B -585M -573M -24.74B
Logo Alamar Biosciences, Inc.
Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications.
Employees
286
Date Price Change Volume
03/09/26 USD 30.46 +3.75% 150,671
01/09/26 USD 29.36 -3.86% 185,086
31/08/26 USD 30.54 -0.55% 325,924
28/08/26 USD 30.71 -6.94% 267,641
27/08/26 USD 33.00 -3.17% 281,360
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
29.36USD
Average target price
33.40USD
Spread / Average Target
+13.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALMR Stock